Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group.
about
Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's diseaseTolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's diseaseReview of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease.Interventions to achieve tonic exposure to levodopa: delaying or preventing the onset of motor complications.Catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease.Economic and health-related quality of life considerations of new therapies in Parkinson's disease.Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month studyCOMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet).Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studiesRole of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations.Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's diseaseCurrent status of symptomatic medical therapy in Parkinson's diseaseSummary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease.Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease.Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites.A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's disease.Twelve-month safety of entacapone in patients with Parkinson's disease.Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations.Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily.Therapeutic advances in idiopathic Parkinsonism.Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.Health-related quality of life following bilateral intrastriatal transplantation in Parkinson's disease.The effect of tolcapone on the pharmacokinetics of benserazide.A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group.Early (Uncomplicated) Parkinson's Disease
P2860
Q24245911-EEFC043C-A568-4166-8B6E-9EA776B4F4EAQ24657680-5F3006B5-5441-4CBC-B36D-C1508128DD62Q33260250-4D72F3A3-B971-4A07-AA0F-3FE6EBB93594Q33771370-754EA851-9F19-478B-A224-B1E3699EC223Q33944053-C15E4E90-FCEB-4916-A19B-F8485430EEC3Q34363332-E21CD102-9B14-4A58-B131-3694AC09D8B0Q35475549-90690237-3AD0-4AB6-ADB7-EC142661D9E9Q36053708-06BFDCEF-E6C9-4FA8-BDD7-8979D8704525Q36054988-B4E1BD56-9E2B-4C10-BC76-2C05CDC5B474Q36094535-24679CCC-549F-4CAE-8B48-8D81446EFCB3Q36227514-536AC73A-E200-441C-992B-8282B2B583A8Q37131229-76969847-9E63-4A9E-8673-DFE2B5E2EB26Q38070888-960235DC-63F7-4EB7-B09D-63E466CFF76AQ38262418-5EDFF4BB-4B50-41FD-A66A-F4BF0057D860Q42536582-5DDE8E1A-9C76-4451-B8CE-8E6E70F0B204Q42680844-A5182907-338C-4E70-8C3E-2608FB0E4B15Q42960879-6FE69B9E-8830-4050-9C77-1BCD5CF509E1Q43709671-4D25689C-F626-4F59-9F38-1735A5538F0AQ43825521-2242F24A-D9EF-47BC-BDB1-66069FB12CA3Q43951950-FCBBF00F-5162-4FA7-BD44-0217137460A5Q46116294-08397B1C-CC4D-408B-BCDA-012EEDC8D7E0Q49115429-77E0010F-2838-4AE5-A105-BD417BB1D25DQ50528372-55C5E732-6A3F-4EDB-8AC7-1096EC9F803DQ53524831-8B43D395-2AC8-4669-AFB4-5444ADB8B4DDQ53936352-81834942-3D7A-4E4B-9BB6-11EE25F8799AQ53948544-D37893F7-8A48-4219-818D-008D42363E4FQ58870319-08DC17E5-BF67-49C5-86E4-7DB3EFE92E93
P2860
Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Tolcapone in stable Parkinson' ...... Tolcapone Stable Study Group.
@en
Tolcapone in stable Parkinson' ...... Tolcapone Stable Study Group.
@nl
type
label
Tolcapone in stable Parkinson' ...... Tolcapone Stable Study Group.
@en
Tolcapone in stable Parkinson' ...... Tolcapone Stable Study Group.
@nl
prefLabel
Tolcapone in stable Parkinson' ...... Tolcapone Stable Study Group.
@en
Tolcapone in stable Parkinson' ...... Tolcapone Stable Study Group.
@nl
P2093
P356
P1433
P1476
Tolcapone in stable Parkinson' ...... Tolcapone Stable Study Group.
@en
P2093
C H Waters
E Dorflinger
L M Shulman
P304
P356
10.1212/WNL.49.3.665
P407
P577
1997-09-01T00:00:00Z